These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 11500820)
1. Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine. Pérez-Melgosa M; Ochs HD; Linsley PS; Laman JD; van Meurs M; Flavell RA; Ernst RK; Miller SI; Wilson CB Eur J Immunol; 2001 Aug; 31(8):2373-81. PubMed ID: 11500820 [TBL] [Abstract][Full Text] [Related]
2. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. Latz E; Franko J; Golenbock DT; Schreiber JR J Immunol; 2004 Feb; 172(4):2431-8. PubMed ID: 14764714 [TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants. Dashefsky B; Wald E; Guerra N; Byers C Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine. Donnelly JJ; Deck RR; Liu MA J Immunol; 1990 Nov; 145(9):3071-9. PubMed ID: 2120344 [TBL] [Abstract][Full Text] [Related]
5. Effect of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate vaccine on macrophages. Ambrosino DM; Bolon D; Collard H; Van Etten R; Kanchana MV; Finberg RW J Immunol; 1992 Dec; 149(12):3978-83. PubMed ID: 1460286 [TBL] [Abstract][Full Text] [Related]
6. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Granoff DM; Rathore MH; Holmes SJ; Granoff PD; Lucas AH Vaccine; 1993; 11 Suppl 1():S46-51. PubMed ID: 8447176 [TBL] [Abstract][Full Text] [Related]
7. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Heath PT Pediatr Infect Dis J; 1998 Sep; 17(9 Suppl):S117-22. PubMed ID: 9781743 [TBL] [Abstract][Full Text] [Related]
8. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. Schlesinger Y; Granoff DM JAMA; 1992 Mar; 267(11):1489-94. PubMed ID: 1538539 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants. Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290 [TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Campagne G; Garba A; Fabre P; Schuchat A; Ryall R; Boulanger D; Bybel M; Carlone G; Briantais P; Ivanoff B; Xerri B; Chippaux JP Pediatr Infect Dis J; 2000 Feb; 19(2):144-50. PubMed ID: 10694002 [TBL] [Abstract][Full Text] [Related]
11. Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. Granoff DM; Holmes SJ; Belshe RB; Osterholm MT; McHugh JE; Anderson EL JAMA; 1994 Oct; 272(14):1116-21. PubMed ID: 7933324 [TBL] [Abstract][Full Text] [Related]
12. Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy. Kurikka S; Käyhty H; Saarinen L; Rönnberg PR; Eskola J; Mäkelä PH J Infect Dis; 1995 Nov; 172(5):1268-72. PubMed ID: 7594663 [TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population. Lottenbach KR; Granoff DM; Barenkamp SJ; Powers DC; Kennedy D; Irby-Moore S; Homan SM; Mink CM J Am Geriatr Soc; 2004 Nov; 52(11):1883-7. PubMed ID: 15507066 [TBL] [Abstract][Full Text] [Related]
14. Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine. Fusco PC; Michon F; Laude-Sharp M; Minetti CA; Huang CH; Heron I; Blake MS Vaccine; 1998 Nov; 16(19):1842-9. PubMed ID: 9795390 [TBL] [Abstract][Full Text] [Related]
15. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Pichichero ME Hum Vaccin Immunother; 2013 Dec; 9(12):2505-23. PubMed ID: 23955057 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis conjugate vaccine in 7.5 micrograms liquid formulation: a comparison of three lots with the 15.0 micrograms lyophilized formulation. Study Group for 7.5 micrograms Liquid PedvaxHIB. Mendelman PM; Feeley L; Bird S; Staub T; Matthews H; Del Beccaro MA; Overturf G; Lee A; Ellis R; Staub J; Szymanski S; Donnelly J; Hennessey JP; Kniskern P Vaccine; 1997; 15(6-7):775-81. PubMed ID: 9178481 [TBL] [Abstract][Full Text] [Related]
17. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine. Weinberg GA; Einhorn MS; Lenoir AA; Granoff PD; Granoff DM J Pediatr; 1987 Jul; 111(1):22-7. PubMed ID: 3110388 [TBL] [Abstract][Full Text] [Related]
18. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Bryant KA; Marshall GS Expert Rev Vaccines; 2011 Jul; 10(7):941-50. PubMed ID: 21806393 [TBL] [Abstract][Full Text] [Related]
19. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. Granoff DM; Anderson EL; Osterholm MT; Holmes SJ; McHugh JE; Belshe RB; Medley F; Murphy TV J Pediatr; 1992 Aug; 121(2):187-94. PubMed ID: 1640282 [TBL] [Abstract][Full Text] [Related]
20. A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes. Liu MA; Friedman A; Oliff AI; Tai J; Martinez D; Deck RR; Shieh JT; Jenkins TD; Donnelly JJ; Hawe LA Proc Natl Acad Sci U S A; 1992 May; 89(10):4633-7. PubMed ID: 1533934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]